中國(guó)乙型肝炎疫苗免疫策略及接種進(jìn)展
摘要:乙型肝炎是全球重要的公共衛(wèi)生問題。我國(guó)通過實(shí)施以乙型肝炎疫苗為核心的綜合防控策略,在乙型肝炎防控方面取得了顯著成效,但仍存在諸多問題和挑戰(zhàn)。本文回顧了我國(guó)乙型肝炎免疫策略的發(fā)展歷程,分析了不同人群的疫苗接種目標(biāo)與進(jìn)展,以及存在的問題及挑戰(zhàn),為進(jìn)一步優(yōu)化免疫策略和提升防控水平提供參考。
關(guān)鍵詞:乙型肝炎疫苗;免疫;接種;疫苗,聯(lián)合
基金項(xiàng)目:國(guó)家自然科學(xué)基金(11571272)
Strategies and advances in hepatitis B vaccination in China
TANG Lin1,2,XU Xia1,2,ZHOU Zemei1,2,WANG Xiaoqi1,2,LIJizhen1,2,YIN Zundong1,2,WANG Fuzhen1,2
1.National Immunization Program,Chinese Center for Disease Control and Prevention,Beijing 100050,China;2.National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases,Chinese Center for Disease Control and Prevention,Beijing 102206,China
Corresponding author:WANG Fuzhen,wangfz@chinacdc.cn(ORCID:0000-0002-6784-7711)
Abstract:Hepatitis B is a major global public health issue.Through the implementation of comprehensive prevention and control strategies centered on hepatitis B vaccination,China has achieved remarkable progress in hepatitis B prevention and control,while there are still many issues and challenges.This article reviews the development of hepatitis B vaccination strategies in China,analyzes the goal and advances in vaccination in different populations,and problems and challenges,in order to provide a reference for further optimizing vaccination strategies and improving the levels of prevention and control.
Key words:Hepatitis B Vaccines;Immunity;Vaccination;Vaccines,Combined
Research funding:National Natural Science Foundation of China(11571272)
乙型肝炎是全球范圍內(nèi)的重大公共衛(wèi)生問題之一。(剩余18759字)
- 建立公共衛(wèi)生管理模式,促進(jìn)消除...
- 中國(guó)慢性乙型肝炎治療的進(jìn)展與挑...
- 中國(guó)乙型肝炎疫苗免疫策略及接種...
- 中國(guó)消除丙型肝炎公共衛(wèi)生危害行...
- 中國(guó)病毒性肝炎疾病負(fù)擔(dān)研究進(jìn)展...
- 海南省消除病毒性肝炎公共衛(wèi)生危...
- 《2024年歐洲肝病學(xué)會(huì)臨床實(shí)...
- 《2024年歐洲肝病學(xué)會(huì)臨床實(shí)...
- 基于限制性立方樣條模型分析絕經(jīng)...
- 1,25(OH)2D3改善膽堿...
- 不同無創(chuàng)診斷模型對(duì)代償期乙型肝...
- 丙型肝炎肝硬化失代償患者再代償...
- 合并肝細(xì)胞癌對(duì)肝硬化食管胃靜脈...
- 線粒體翻譯起始因子(MTIF2...
- 五倍子酸對(duì)肝癌HepG2細(xì)胞索...
- 鱉甲煎丸調(diào)控AKT/mTOR信...
- 62例不明原因肝內(nèi)膽汁淤積的病...
- 基于CT圖像的腹部肌肉內(nèi)部分層...
- 層粘連蛋白α3亞基(LAMA3...
- 經(jīng)口膽道鏡聯(lián)合經(jīng)皮膽道穿刺引流...
- 幽門螺桿菌感染與HBV感染相關(guān)...
- HBV感染與線粒體穩(wěn)態(tài)相互作用...
- 中藥調(diào)控免疫細(xì)胞治療肝細(xì)胞癌的...
- 肝細(xì)胞癌合并膽管癌栓的診療進(jìn)展...
- 慢性膽汁淤積性肝病基礎(chǔ)上發(fā)生藥...
- 肝性腦病中醫(yī)/壯醫(yī)“濁毒致病”...
- 生物堿類化合物調(diào)控慢性肝病的作...
- 髓系細(xì)胞觸發(fā)受體2(TREM2...
- 自噬在對(duì)乙酰氨基酚誘導(dǎo)肝損傷中...
- 自身免疫性胰腺炎合并胰腺外分泌...
- Hepatology|多中心、...
- Journal of Hepa...
- Journal of Hepa...
- Liver Internati...
- 《臨床肝膽病雜志》關(guān)于利益沖突...
- 《臨床肝膽病雜志》關(guān)于倫理審查...
- 《臨床肝膽病雜志》入選“中國(guó)科...
- 《臨床肝膽病雜志》2025年1...
- 《臨床肝膽病雜志》入選“全球O...
- 《臨床肝膽病雜志》入選“中國(guó)開...
- 《臨床肝膽病雜志》入選“學(xué)術(shù)誠(chéng)...
- 本期審稿專家...